Skip to content

Clinical Validation of Remimazolam Target-Controlled Infusion System

Clinical Validation of Remimazolam Target-Controlled Infusion System

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123096
Enrollment
Unknown
Registered
2026-04-21
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Remimazolam group:Collect blood samples from patients at different time points

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 75 years (inclusive), regardless of gender; 2. Patients scheduled for elective general anesthesia for thoracic surgery with a hospital stay of =3 days; 3. Expected surgical duration of 1 to 2 hours; 4. ASA physical status classification of I or II; 5. Body mass index (BMI) between 18 kg/m^2 and 30 kg/m^2 (exclusive of the boundaries); 6. Fully understand the study, voluntarily participate, and personally sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergy to benzodiazepines; 2. Severe respiratory diseases (including acute respiratory infections); 3. Acute heart failure; 4. Moderate to severe valvular heart disease; 5. Psychiatric disorders, long-term use of psychotropic medications, or cognitive dysfunction; 6. Abnormalities in liver, kidney, or coagulation function; 7. History of benzodiazepine use, substance abuse, or alcohol abuse within 2 years prior to the screening period.

Design outcomes

Primary

MeasureTime frame
Plasma concentrations of remimazolam at different time points ;

Countries

China

Contacts

Public ContactWu Jingxiang

Shanghai Chest Hospital

wjx1132@163.com+86 21 22200000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026